INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neogen Corporation

The FDA issued Neogen a warning letter after linking its sterile-labeled veterinary wound-care product HYCOAT to serious infections and at least 20 horse deaths; Neogen had initiated a voluntary recall in late January 2026. On September 29, 2026, Neogen shares fell $0.99, or 7.22%, to close at $12.73. Pomerantz LLP announced an investigation into potential securities fraud or other unlawful business practices by Neogen and certain officers or directors.

Analysis

The key issue is whether investors treat this as an isolated product-control failure or evidence of a broader quality-system weakness. The former could mean contained remediation, legal expense and customer friction; the latter raises the risk of expanded FDA scrutiny, more costly controls, delayed launches and substitution by alternative suppliers. Do not extrapolate one product incident to Neogen’s entire portfolio without evidence. Competitors in veterinary wound care could benefit at the margin if clinics avoid the product, but the article does not identify substitutes or quantify displaced demand.

The securities-fraud investigation is a plaintiff-firm solicitation, not a finding of misconduct; it is a weak incremental catalyst by itself. The more material signals are FDA follow-up, any expansion of corrective action, and measurable effects on sales or guidance. The reported share-price decline occurred on September 29, so this October 29 item is not a fresh event catalyst. Near term, headline-driven volatility may persist; over 1–3 months, watch for regulatory updates and company disclosures. Over 6–18 months, customer retention and evidence of remediation determine whether this remains a contained charge or a trust/quality-system overhang.

The contrarian risk is assuming the incident is immaterial because the product may be narrow: severity could invite scrutiny beyond the product itself. Conversely, treating the law-firm announcement as proof of broader liability overstates what is known. Before sizing a directional position, verify the affected product’s revenue, recall costs, insurance coverage, any broader FDA findings, and current valuation and options pricing.

Key Decisions for Investors

• Do not initiate a short solely on the class-action announcement; it adds little beyond the already-public FDA event and is not a legal finding.
• Keep NEOG on a regulatory watchlist. Reassess promptly if FDA action expands beyond the affected product, the company discloses material remediation costs, or guidance/customer retention weakens.
• If those broader signals emerge, consider a defined-risk NEOG put spread rather than an unbounded short; first compare implied volatility with the expected timing of regulatory or earnings catalysts.
• A recovery/long thesis requires confirmation that corrective actions are accepted and the incident remains contained. Falsifiers include further product actions, adverse FDA findings, or a material downward revision to company guidance.